Microsoft shares jump after fourth-quarter earnings beat on AI-fueled cloud growth
NEW YORK - Liminatus Pharma, Inc. (NASDAQ:LIMN), a $168 million market cap biotech company whose shares have surged over 18% in the past week, has entered into an engagement agreement with Digital Offering LLC to serve as its exclusive placement agent for a potential strategic capital raise, according to a press release issued Thursday.
The preclinical-stage biopharmaceutical company, which focuses on targeted cancer immunotherapies, said the engagement supports its previously disclosed review of a digital asset treasury strategy as it evaluates modern financial tools to strengthen its capital structure. According to InvestingPro data, the company is not yet profitable, with a P/E ratio of -47x, highlighting the importance of this strategic financial move.
Under the agreement, Digital Offering, a FINRA- and SEC-registered broker-dealer, will assist Liminatus in sourcing institutional and digital asset-focused investors and structuring a compliant financing solution.
The potential funding initiative may involve various exempt financing structures, including convertible debentures, equity-linked securities, or other alternative instruments that comply with U.S. securities laws.
"At Liminatus, our core mission is advancing transformative immunotherapies for cancer," said Chris Kim, CEO of Liminatus. "As we work toward that goal, we are also taking proactive steps to strengthen our capital strategy."
The company emphasized that no financing transaction has been finalized, and any potential capital transaction would remain subject to the Board of Directors’ approval and full regulatory compliance.
Liminatus is developing a pipeline of novel therapies targeting cancer antigens and tumor-specific immune responses. The company stated the engagement with Digital Offering relates strictly to placement agent services. InvestingPro analysis reveals several additional key metrics and insights about Liminatus’s financial health and market position. Subscribers can access comprehensive financial analysis, including 7 more exclusive ProTips and detailed valuation metrics.
In other recent news, Liminatus Pharma has announced several significant developments. The company has formed a consortium with Samda Biolab Co., Ltd. and INNOCS AI to develop a novel blood-based diagnostic kit for early detection of pancreatic cancer. This initiative utilizes a deep learning algorithm and a panel of 16 metabolomic biomarkers, demonstrating high sensitivity and specificity in recent clinical data. Additionally, Liminatus Pharma has entered into a settlement agreement with Alta Partners, exchanging 1 million warrants for 350,000 shares of common stock. The transaction was completed without any commission or remuneration and relied on an exemption from registration under the Securities Act of 1933.
Furthermore, Liminatus Pharma has expanded its board of directors by appointing Philip Lemons and Richard Baek, increasing the board to six members. Lemons brings over twenty years of experience in clinical research and development. In another strategic move, the company is exploring the potential inclusion of regulated digital assets in its treasury management framework. Lastly, Liminatus Pharma has regained compliance with Nasdaq’s listing requirements after addressing a delay in filing its quarterly report, a development that was well-received in the market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.